Utility of 2013 American College of Cardiology/American Heart Association Cholesterol Guidelines in HIV-Infected Adults With Carotid Atherosclerosis
Open Access
- 1 July 2017
- journal article
- research article
- Published by Wolters Kluwer Health in Circulation: Cardiovascular Imaging
- Vol. 10 (7) , e005995
Abstract
Background—: Although HIV is associated with increased atherosclerotic cardiovascular disease (CVD) risk, it is unknown whether guidelines can identify HIV-infected adults who may benefit from statins. We compared the 2013 American College of Cardiology/American Heart Association and 2004 Adult Treatment Panel III recommendations in HIV-infected adults and evaluated associations with carotid artery intima-media thickness and plaque. Methods and Results—: Carotid artery intima-media thickness was measured at baseline and 3 years later in 352 HIV-infected adults without clinical atherosclerotic CVD and not on statins. Plaque was defined as IMT >1.5 mm in any segment. At baseline, the median age was 43 (interquartile range, 39–49), 85% were men, 74% were on antiretroviral medication, and 50% had plaque. The American College of Cardiology/American Heart Association guidelines were more likely to recommend statins compared with the Adult Treatment Panel III guidelines, both overall (26% versus 14%; P P =0.0002), and in those without plaque (16% versus 7%; P =0.025). In multivariable analysis, older age, higher low-density lipoprotein cholesterol, pack per year of smoking, and history of opportunistic infection were associated with baseline plaque. Baseline IMT (hazard ratio, 1.18 per 10% increment; 95% confidence interval, 1.05–1.33; P =0.005) and plaque (hazard ratio, 2.06; 95% confidence interval, 1.02–4.08; P =0.037) were each associated with all-cause mortality, independent of traditional CVD risk factors. Conclusions—: Although the American College of Cardiology/American Heart Association guidelines recommended statins to a greater number of HIV-infected adults compared with the Adult Treatment Panel III guidelines, both failed to recommend therapy in the majority of HIV-affected adults with carotid plaque. Baseline carotid atherosclerosis but not atherosclerotic CVD risk scores was an independent predictor of mortality. HIV-specific guidelines that include detection of subclinical atherosclerosis may help to identify HIV-infected adults who are at increased atherosclerotic CVD risk and may be considered for statins.Keywords
This publication has 26 references indexed in Scilit:
- Immunologic Basis of Cardiovascular Disease in HIV-Infected AdultsThe Journal of Infectious Diseases, 2012
- Cardiovascular Risk Estimation in 2012: Lessons Learned and Applicability to the HIV PopulationThe Journal of Infectious Diseases, 2012
- Carotid Intima‐Media Thickness Progression in HIV‐Infected Adults Occurs Preferentially at the Carotid Bifurcation and Is Predicted by InflammationJournal of the American Heart Association, 2012
- Carotid Intima-Media Thickness Among Human Immunodeficiency Virus–Infected Patients Without Coronary CalciumThe American Journal of Cardiology, 2012
- Preclinical atherosclerosis due to HIV infection: carotid intima-medial thickness measurements from the FRAM studyAIDS, 2009
- The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trialsBMJ, 2009
- Role of viral replication, antiretroviral therapy, and immunodeficiency in HIV-associated atherosclerosisAIDS, 2009
- Increased carotid intima-media thickness in HIV patients is associated with increased cytomegalovirus-specific T-cell responsesAIDS, 2006
- What a Cardiologist Needs to Know About Patients With Human Immunodeficiency Virus InfectionCirculation, 2005
- Progression of Atherosclerosis as Assessed by Carotid Intima-Media Thickness in Patients With HIV InfectionCirculation, 2004